Plasmin modulates neutrophilic inflammation and alveolar macrophage function, protecting mice from pneumococcal pneumonia
Accumulating evidence supports pro-resolving actions of the Plasminogen/Plasmin (Plg/Pla) system during inflammation, beyond its classical role in fibrin degradation. Here, we investigated the role of Plg/Pla on key features of inflammation resolution in a murine model of severe pneumococcal pneumonia. High levels of Plg were observed in the airways following infection, accompanied by increased levels of plasminogen activator inhibitor-1, neutrophil elastase and Plg degradation fragments as inflammation progressed. Pla treatment of mice infected with Streptococcus pneumoniae (Sp) decreased neutrophilic infiltration in airways and lungs, accompanied by lower concentrations of the neutrophil chemoattractive chemokines CXCL1 and CXCL2, as well as the pro-inflammatory cytokines TNF, IL-6, and IL-1β. Pla-treatment also enhanced neutrophil apoptosis and efferocytosis, and slightly reduced bacterial loads in bronchoalveolar lavage. In addition, Pla decreased damage and fibrin deposition in lungs, improving pneumonia-driven pulmonary mechanical dysfunction, and rescuing mice from lethality. Pla-induced resolution of Sp-evoked inflammation was associated with neutrophil apoptosis, as the caspase-3 specific inhibitor Z-DEVD-FMK blocked Pla protective actions. In addition to the effects on neutrophils, intranasal instillation of Pla in naïve mice increased the number of alveolar macrophages and guided them toward a regulatory phenotype marked by enhanced efferocytosis of apoptotic neutrophils and increased bacterial phagocytosis, ultimately promoting host protection against pneumococcus-induced inflammation and tissue damage. In sum, our findings demonstrate that plasmin modulates the lung inflammatory milieu and promotes key pro-resolving events, namely neutrophil apoptosis and expansion of alveolar macrophage with enhanced efferocytosis and phagocytic abilities, resulting in improved lung function and survival in pneumococcal pneumonia.
Authors
- Robert J. Parmer (ORCID: https://orcid.org/0000-0003-4197-0241)
- Luciana P. Tavares (ORCID: https://orcid.org/0000-0002-5319-0210)
- Michelle A. Sugimoto (ORCID: https://orcid.org/0000-0002-4527-6065)
- Franciel Batista Félix (ORCID: https://orcid.org/0000-0002-2372-2781)
- Mauro Martins Teixeira (ORCID: https://orcid.org/0000-0002-6944-3008)
- Fernanda Silva Carneiro
- Érick Bryan de Sousa Lima (ORCID: https://orcid.org/0000-0003-2052-2976)
- L P Sousa
- Camila Cardoso (ORCID: https://orcid.org/0000-0001-8131-579X)
- Juliana P. Vago (ORCID: https://orcid.org/0000-0001-8188-3738)
- Lindsey A Miles
- Rodrigo Severo Caixeta
- Edvaldo S. Lara
- Isabella L. Augusto
- Vivian Vasconcelos Costa
- Remo Castro Russo
- Antônio Felipe Silva Carvalho
- Fernão Castro Braga
- Celso Martins Queiroz-Junior
- Ana Clara M. Montuori-Andrade
- Adelson H. A. Monteiro
- Lais C Grossi
- Vanessa Pinho
- Jéssica A. M. Souza
- Bárbara C. M. Barbosa
Institutions
- Universidade Federal de Minas Gerais (BR)
- Scripps Research Institute (US)
- University of California San Diego (US)
Publication Details
- Journal
- Blood
- Published
- 2026-01-20
- DOI
- https://doi.org/10.1182/blood.2025028733
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00